The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
mRNA-1010 demonstrated superior relative vaccine efficacy
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
